.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,017,615

« Back to Dashboard

Claims for Patent: 4,017,615

Title: Propylene carbonate ointment vehicle
Abstract:An ointment vehicle containing from 0.5 to 30 percent propylene carbonate, from 30 to 99.5 weight percent petrolatum and/or polysiloxane, compatible cosolvent, the concentration of which in combination with propylene carbonate is from 0.5 to 70 percent, and, optionally, surfactants, thickeners, preservatives, and penetrants. This ointment is a suitable vehicle for all types of therapeutic agents for topical application including antibiotics, steroids, antihistamines, antiseptics, anesthetics, antibacterials, fungicides and the like, and has shown particular advantages with anti-inflammatory topical corticoids.
Inventor(s): Shastri; Subramaniam (Cupertino, CA), Shaikh; Zafaruzzaman I. (Palo Alto, CA)
Assignee: Syntex Corporation (Panama, PM)
Application Number:05/639,740
Patent Claims: 1. An ointment comprising an ointment base consisting essentially of

a. from 0.5 to 30 weight percent propylene carbonate;

b. from 30 to 99.5 weight percent petrolatum, polysiloxane having a viscosity of from 0.5 to 10.sup.6 centistokes, or mixtures thereof;

c. compatible co-solvent, the concentration of which in combination with the propylene carbonate is from 0.5 to 70 weight percent;

d. from 0 to 45 weight percent pharmaceutically acceptable surfactant;

e. from 0 to 20 weight percent thickener; and

f. from 0 to 25 weight percent penetrant

in combination with a therapeutically effective amount of a propylene carbonate soluble medicament.

2. The ointment of claim 1 wherein the medicament is a topically active anti-inflammatory steroid.

3. The ointment of claim 2 wherein the steroid is

a. a pregn-4-ene-3,20-dione having at each of positions C-1,2 and C-6,7, a single bond, double bond or group having the formula ##STR5## wherein R.sub.11 and R.sub.12 each is hydrogen, chloro or fluoro; at position C-6, hydrogen, methyl, fluoro or chloro; at position C-9, hydrogen, chloro, or fluoro; at position C-11, keto or ##STR6## wherein R.sub.3 ' is hydrogen, hydroxy, chloro or fluoro; at position C-16, hydrogen, methyl, hydroxy or conventional hydrolyzable esters thereof, at position C-17.alpha., hydrogen, hydroxy, conventional hydrolyzable esters thereof, or when taken together with C-16.alpha., a group having the formula ##STR7## wherein R.sub.6 is hydrogen or alkyl of up to 8 carbons, and R.sub.7 is hydrogen, or alkyl or aryl having up to 8 carbons; and at position C-21, hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy, tetrahydrofuranyloxy, 4'-(lower)alkoxytetrahydropyran-4'-yloxy, lower alkoxy, lower cycloalkoxy, lower cycloalkenyloxy, chloro or fluoro; or

b. a 2'-substituted-pregn-4-en-20-one-[3,2-c]pyrazole or a 1'-substituted-pregn-4-en-20-one-[3,2-c]-pyrazole having at the respective N-2' or N-1' positions, hydrogen, methyl, phenyl, chlorophenyl, fluorophenyl, methylphenyl, or methoxyphenyl, and having at C-6,7, a single bond, double bond or group having the formula ##STR8## wherein R.sub.11 and R.sub.12 each is hydrogen, chloro or fluoro; at position C-6, hydrogen, methyl fluoro or chloro; at position C-9, hydrogen, chloro or fluoro; at position C-11, keto or ##STR9## wherein R.sub.3 ' is hydrogen, hydroxy, chloro or fluoro; at position C-16, hydrogen, methyl, hydroxy or conventional hydrolyzable esters thereof, at position C-17.alpha., hydrogen, hydroxy, conventional hydrolyzable esters thereof, or when taken together with C-16.alpha., a group having the formula ##STR10## wherein R.sub.6 is hydrogen or alkyl of up to 8 carbons, and R.sub.7 is hydrogen, or alkyl or aryl having up to 8 carbons; and at position C-21, hydroxy, conventional hydrolyzable esters thereof, tetrahydropyranyloxy, tetrahydrofuranyloxy, 4'-(lower)alkoxytetrahydropyran-4'-yloxy, lower alkoxy, lower cycloalkoxy, lower cycloalkenyloxy, chloro or fluoro.

4. The ointment of claim 3 wherein the steroid is 6.alpha.,9.alpha.-difluoro-11.beta.-hydroxy-16.alpha.,17.alpha.-isopropyli denedioxy-21-acetoxypregna-1,4-diene-3,20-dione.

5. The ointment of claim 3 wherein the steroid is 6.alpha.,9.alpha.-difluoro-11.beta.,21-dihydroxy-16.alpha.,17.alpha.-isopr opylidenedioxypregna-1,4-diene-3,20-dione.

6. The ointment of claim 3 wherein the steroid is 6.alpha.-fluoro-9.alpha.,11.beta.-dichloro-16.alpha.,17.alpha.-isopropylid enedioxy-21-hydroxypregna-1,4-diene-3,20-dione.

7. The ointment of claim 3 wherein the steroid is 9.alpha.,11.beta.-dichloro-6.alpha.,21-difluoro-16.alpha.,17.alpha.-isopro pylidenedioxypregna-1,4-diene-3,20-dione.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc